Patritumab was also evaluated in combination with erlotinib for NSCLC, with cetuximab and platinum-based chemotherapy for HNSCC, and with trastuzumab and paclitaxel for HER2 positive breast cancer. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.